ReviewFrontiers in cardiovascular medicine2025
Role of gut microbiota and its metabolites in diabetic cardiomyopathy: from pathogenesis to interventions.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy (DCM), a prevalent cardiovascular complication and the principal driver of mortality among patients with diabetes, represents a significant clinical challenge. The gut microbiota, which reside a complex ecosystem within the human intestinal tract, play a fundamental role in host metabolism and systemic physiology. Mounting evidence underscores a critical link between gut microbial dysbiosis, microbial-derived metabolites, and DCM pathogenesis mediated through the gut-heart axis. This comprehensive review systematically synthesizes the current research elucidating the multifaceted interplay between the gut microbiota, their bioactive metabolites (e.g., short-chain fatty acids, bile acids, and branched-chain amino acids), and the development and progression of DCM. By critically evaluating the mechanisms underlying the gut-heart crosstalk, we provide novel insights into the etiopathogenesis of DCM. Furthermore, we evaluated emerging therapeutic strategies aimed at mitigating DCM by targeted modulation of the gut microbiota and their metabolic output, highlighting promising avenues for future research and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.